A carregar...
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor receptor inhibitors. This randomized phase 2 trial evaluated apricoxib, a novel COX-2 inhibitor, in combination with erlotinib in bi...
Na minha lista:
| Publicado no: | J Thorac Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4271824/ https://ncbi.nlm.nih.gov/pubmed/24736085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000082 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|